Evaluation of an amsacrine analog in a human tumor cloning system.
A human tumor-cloning system was used to compare the antitumor activity of CI-921, a new amsacrine analog with that of its parent compound (amsacrine gluconate). A total of 48 specimens of 9 histologically different types of human malignancy were evaluable for a direct comparison of the cytotoxic activity. Both compounds were tested simultaneously at 10 micrograms/ml final concentration under continuous exposure. The overall activity was similar for both drugs, but the degree of cross-resistance was low. We concluded that in patients, CI-921 might have a different spectrum of antitumor activity from that of its parent compound.
Lathan
B
B
University of Cologne, First Medical Department, Federal Republic of Germany.
Von Hoff
D D
DD
Clark
G M
GM
Elslager
E E
EE
D000677:Amsacrine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000970:Antineoplastic Agents; D001943:Breast Neoplasms / Q000473:pathology; D003110:Colonic Neoplasms / Q000473:pathology; D004351:Drug Resistance; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology; D014407:Tumor Cells, Cultured / Q000187:drug effects*; D014410:Tumor Stem Cell Assay / Q000379:methods
D000970:Antineoplastic Agents; D000677:Amsacrine; C042315:asulacrine